Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Dosimetry of /sup 131/I-labeled anti-ferritin in hepatoma: a model for radioimmunoglobulin dosimetry

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
Dosimetric studies are reported for four hepatoma patients treated with /sup 131/I-labeled anti-ferritin following combination radiation and chemotherapy. Administered activities of radiolabeled antibody ranged from 93 to 157 mCi. Studies included liver and tumor volume calculations from sequences of computerized axial tomographic (CAT) scan slices, in-vivo quantitation of radiolabeled antibody in the liver and tumor, determination of kinetic parameters of radioimmunoglubulin for liver, tumor, and the total body, and computation of dose rates (rad/hour) and dose (rad) for these tissues. Mean values of the effective half-life for radiolabeled antibody in the liver and tumor were 7.4 days and for total-body activity 3.6 days, respectively. For the four patients, the calculated /sup 131/I radiation dose for tumor tissue ranged from 1500 to 2200 rad, for liver tissue from 400 to 1000 rad, and for total-body irradiation (TBI) from 110 to 220 rad.
OSTI ID:
6582462
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 7:3; ISSN IOBPD
Country of Publication:
United States
Language:
English